Transaction in Own Shares
BioPharma Credit plc
(the "Company")
TRANSACTION IN OWN SHARES
BioPharma Credit PLC announces that today it has purchased the following number of its ordinary shares of US$0.01 through J.P. Morgan Securities plc into treasury.
Ordinary Shares: BPCR LN
Date of purchase: 10 April 2024
Number of ordinary shares purchased: 324,274
Lowest price per share: $0.8740
Highest price per share: $0.8780
Trading venue: London Stock Exchange
Ordinary Shares: BPCR LN
Date of purchase: 10 April 2024
Number of ordinary shares purchased: 1,400,000
Lowest price per share: $0.8760
Highest price per share: $0.8780
Trading venue: JPSI
Ordinary Shares: BPCR LN
Date of purchase: 10 April 2024
Number of ordinary shares purchased: 5,000
Lowest price per share: $0.8760
Highest price per share: $0.8760
Trading venue: JPM-ETR
Aggregate volume per date per trading venue: 1,729,274
Weighted average price per day per trading venue: $0.8775
Following the above transaction, the Company holds 132,209,122 of its ordinary shares in treasury and has 1,241,722,945 ordinary shares in issue (excluding treasury shares). Therefore, the total number of voting rights in the Company is 1,241,722,945. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
+44 (0) 333 300 1950
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0)20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 10 minutes ago Auction Technology Group
- 40 minutes ago Wise Class A
- 51 minutes ago Sage Group
- 1 hour ago On The Beach Group
- 1 hour ago MJ Gleeson